Developer docs
API playgroundTry for free, no card

Search company profiles

Odylia

Full company profile

uuid000ec4d

Namestring
Odylia
Legal namestring
Odylia Therapeutics
Websiteurl
odylia.org
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Odylia Therapeutics is a nonprofit 501(c)(3) biotechnology organization founded in 2017 and headquartered in Atlanta, Georgia, that develops AAV-based gene therapies for rare diseases—predominantly inherited retinal dystrophies—that lack commercial interest from traditional pharmaceutical companies. The organization holds exclusive rights to the Anc80 AAV vector platform (an ancestral adeno-associated virus discovered in 2015 at Massachusetts Eye and Ear) for rare and ultra-rare retinal diseases, and operates a three-program pipeline: OT-004 (RPGRIP1 gene therapy for LCA6, CORD13, and juvenile retinitis pigmentosa, which holds FDA Orphan Drug and Rare Pediatric Disease Designations), a USH1C gene therapy partnered with the Usher 2020 Foundation, and an NPHP1 gene therapy co-developed with the NPHP1 Family Foundation and Boston Children's Hospital. Ancillary to the pipeline, Odylia runs Brydge Solutions, a consulting and portfolio management service for patient advocacy groups, and The Odylia Collective, a marketplace platform (merged with Comend in 2025) that connects patient advocacy groups with drug development service providers such as CROs and CDMOs.

Odylia's business model is philanthropic rather than commercial: the organization is funded by competitive research grants (e.g., $1.5 million from Foundation Fighting Blindness in 2024 and $249,719 from the Critical Path Institute in 2026), individual and corporate donations, and fee-based Brydge Solutions consulting engagements offered at reduced rates to patient groups. Manufacturing partnerships with Andelyn Biosciences (Anc80-capable CDMO) and Aldevron (plasmid DNA) support pipeline progression, while a strategic collaboration with PTC Therapeutics covers retinal disease development using the Anc80 system. Co-founder Luk Vandenberghe (Anc80 discoverer) and CEO/CSO Ashley Winslow lead scientific direction, supported by a Board of Directors with deep rare-disease industry expertise (Ultragenyx founder Emil Kakkis, former Sarepta/Alexion executives).

The organization serves three primary constituents: rare disease patient advocacy groups seeking to develop therapies for conditions with no commercial sponsor, early-stage biotechs and academic researchers needing translational guidance, and pharmaceutical companies pursuing nonprofit partnership models for ultra-rare indications. Go-to-market is community-led and event-driven, leveraging industry conferences (ASGCT, World Orphan Drug Congress), educational webinars, and direct patient-group engagement. As a pre-clinical stage nonprofit, Odylia has no commercial product revenue, and its measurable outputs are grant dollars secured, partnerships established, and IND-enabling milestones achieved across the pipeline.

Short descriptiontext

Odylia Therapeutics is a nonprofit 501(c)(3) biotech developing AAV gene therapies for ultra-rare inherited retinal diseases using the proprietary Anc80 vector platform. It serves patient advocacy groups through a three-program pipeline and a Brydge Solutions consulting service.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease gene therapy, AAV vector therapeutics, nonprofit biotech, retinal dystrophy treatments, drug development consulting
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Nonprofit Rare Disease Gene Therapy Development
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Donations and Charitable Contributions
TypeGrants Donations
Description

Odylia is a 501(c)(3) nonprofit organization that relies on contributions from individuals, nonprofit organizations, patient groups, and corporate donors to fund drug development activities.

odylia.org
2Research Grants
TypeGrants Donations
Description

Odylia receives competitive research grants from foundations and organizations such as the Critical Path Institute ($249,719 grant for USH1C gene therapy) and Foundation Fighting Blindness ($1.5 million Translational Research Award for RPGRIP1).

3Brydge Solutions Services
TypeProfessional Services
Description

Odylia provides consulting and program management services to patient groups, early-stage biotech companies, and academic researchers through its Brydge Solutions initiative, offering services at reduced rates to patient groups.

odylia.org
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Brydge Solutions
Description

A consulting and portfolio management service for rare disease patient groups, providing scientific team support, strategic briefs, landscape analyses, and portfolio management services.

odylia.org
+1 more record
Core offering1 text field

Odylia Therapeutics is a nonprofit biotech developing investigational AAV gene therapies for rare genetic diseases, with a primary focus on inherited retinal dystrophies. Its pipeline includes OT-004 (RPGRIP1), USH1C, and NPHP1 gene therapy programs built on the Anc80 AAV vector platform. The organization also operates Brydge Solutions, providing drug development consulting and portfolio management to patient advocacy groups, and runs The Odylia Collective (merged with Comend), a marketplace connecting patient groups with drug development service providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Accelerated timelines and reduced costs compared to traditional biotech model
+1 more record
Product overview1 text field

Odylia Therapeutics is a nonprofit biotech that operates primarily through its gene therapy pipeline, offering three investigational AAV gene therapies (OT-004/RPGRIP1, USH1C, and NPHP1) built on exclusive Anc80 vector technology. The company complements its internal pipeline with Brydge Solutions—a consulting and portfolio management service for patient groups—and The Odylia Collective marketplace (merged with Comend) that connects patient advocacy groups with drug development service providers. Anc80 Resources provides technical information on the AAV vector platform. The Odylia Library offers educational content and landscape analyses to support the rare disease community.

Product and service5 records
1OT-004 (RPGRIP1 Gene Therapy)
CategoryGene Therapy Pipeline
Description

Investigational AAV gene therapy utilizing the Anc80 vector for efficient RPGRIP1 gene transfer to treat vision loss in patients with Leber Congenital Amaurosis 6 (LCA6), Cone Rod Dystrophy 13 (CORD13), and juvenile retinitis pigmentosa caused by RPGRIP1 mutations.

2USH1C Gene Therapy
CategoryGene Therapy Pipeline
Description

Investigational gene therapy designed to address vision loss in Usher Syndrome Type 1C by delivering a functional copy of the USH1C gene to retinal cells using an AAV delivery system. Developed in partnership with Usher 2020 Foundation.

3NPHP1 Gene Therapy
CategoryGene Therapy Pipeline
Description

AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene, developed in co-development partnership with the NPHP1 Family Foundation and Boston Children's Hospital (Dr. Friedhelm Hildebrandt's team).

4Brydge Solutions
CategoryConsulting Services
Description

Consulting and program management services for rare disease patient groups, providing scientific expertise, strategic briefs, landscape analyses, and portfolio management to accelerate therapeutic development. Services offered at reduced rates to patient groups and include Science Team support, Strategic Briefs, Landscape Analyses, Portfolio Management, and Strategy Evaluations.

5The Odylia Collective (merged with Comend)
CategoryMarketplace Platform
Description

Centralized marketplace designed to make essential drug development resources findable and accessible for patient advocacy groups and the rare disease research community. Connects patient groups with service providers including manufacturers, clinical CROs, animal testing services, cell line producers, and biobanking services.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Usher 2020 Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Partnership to pursue treatment for Usher Syndrome Type 1C-associated vision loss. Preclinical studies supported by the foundation demonstrated successful gene delivery with expression of human USH1C transcript and protein, providing proof-of-concept.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-13
Description

Strategic partnership to launch a patient-driven platform for rare disease drug development. The Odylia Collective concept merged with Comend's platform to help patient advocacy groups identify, evaluate, and partner with service providers like CROs, academic groups, and drug discovery organizations. The partnership was formalized in late 2024 with platform launch planned for April 2025.

3NPHP1 Family Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-05
Description

Innovative co-development partnership to create an AAV-based gene replacement therapy for retinal dystrophy caused by NPHP1 gene mutations. Preclinical work scheduled throughout 2025, targeting IND submission and clinical trial in late 2027.

odylia.org
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-05
Description

Collaboration for NPHP1 gene therapy program. Dr. Hildebrandt's team at Boston Children's Hospital is conducting natural history, dosing, and efficacy studies on two different NPHP1 mouse models. Dr. Hildebrandt is a renowned expert on nephrocystin genes and associated ciliopathies.

5PURA Syndrome Foundation
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-12-17
Description

Partnership to evaluate current state of research and clinical progress toward treatments for PURA Syndrome. Odylia provides scientific and strategic guidance to help the foundation seek new treatments and develop research strategies.

odylia.org
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Partnership to provide scientific and strategic guidance regarding current state of research and clinical progress toward treatments for Smith-Kingsmore syndrome. Odylia's work enables the foundation to deploy resources effectively and develop short- and long-term research strategies.

7JEM Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

Partnership to accelerate development of JEM's portfolio, starting with TECPR2-related disease (SPG49). Odylia develops and implements scientific strategy to accelerate development timelines and increase likelihood of success.

odylia.org
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-31
Description

Partnership with gene therapy CDMO to manufacture OT-004 (RPGRIP1 gene therapy) using the novel Anc80 AAV capsid. Andelyn has unique capabilities to manufacture this novel AAV capsid and bring the treatment to clinical trials.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-21
Description

Partnership to provide scientific and strategic guidance regarding research and clinical progress for CLOVES syndrome treatments. Odylia enables the community to deploy resources effectively and develop ongoing research strategies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-02-24
Description

Partnership to provide scientific and strategic guidance regarding current state of research and understanding of SATB2-associated syndrome. Odylia enables the foundation to deploy resources appropriately to accelerate research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-07-01
Description

Strategic collaboration to develop novel gene therapies for rare inherited retinal diseases utilizing the Anc80 vector system. Lead program is RP-GRIP1 (RPGRIP1) for Leber Congenital Amaurosis 6 (LCA6).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-06-27
Description

Partnership with contract manufacturing organization specializing in plasmid DNA production. Aldevron is a member of Odylia and serves as the exclusive provider of plasmid DNA for Odylia-sponsored projects.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The pioneering nonprofit drug development organization that funded and incubated therapies now marketed by Vertex Pharmaceuticals. Operates an analogous mission-driven, patient-anchored model for ultra-rare genetic disease drug development, the exact organizational archetype Odylia aspires to replicate in retinal disease.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases (including achromatopsia, X-linked retinitis pigmentosa) as well as CNS and salivary gland conditions. Directly competes with Odylia's RPGRIP1, USH1C, and NPHP1 programs in the inherited retinal dystrophy space.

TypeDirect peer
Description

Clinical and commercial-stage AAV gene therapy platform company with approved therapy ABECMA-related assets and a broad pipeline including ABBV-RGX-314 for wet AMD and diabetic retinopathy. Operates the same AAV delivery platform category as Odylia's Anc80-based programs.

TypeBroad incumbent
Description

Acquired by Roche in 2019, Spark developed and commercializes LUXTURNA, the first FDA-approved AAV gene therapy for an inherited retinal dystrophy (RPE65-related). Sets the regulatory and commercial precedent for the exact disease category Odylia targets.

TypeDirect peer
Description

Clinical-stage gene therapy company with a proprietary AAV discovery platform (Therapeutic Vector Evolution) developing treatments for rare diseases including choroideremia and other inherited retinal dystrophies. Competes directly with Odylia on next-generation AAV platforms for ultra-rare ophthalmic diseases.

TypeDirect peer
Description

Clinical-stage biotechnology company developing gene therapies for inherited retinal diseases including retinitis pigmentosa and Stargardt disease. Directly comparable target indication space (inherited retinal dystrophies) and development stage to Odylia's OT-004 program.

TypeOthers
Description

Largest nonprofit funder of retinal degenerative disease research, and a direct financial backer of Odylia via a $1.5M Translational Research Award. Functions as an adjacent ecosystem enabler/funder rather than a competitor, but shapes the competitive landscape by funding competing academic and commercial retinal disease programs.

TypeDirect peer
Description

Nonprofit organization that funds and accelerates Duchenne muscular dystrophy drug development, including direct investment in gene therapy programs and partnerships with Sarepta and other developers. Direct operational analog to Odylia's nonprofit biotech model applied to a different rare disease.

TypeBroad incumbent
Description

Commercial-stage rare disease biotech with multiple approved therapies and an active gene therapy pipeline including programs in ophthalmology. Shares board overlap with Odylia (Emil Kakkis as CEO, Khandan Baradaran as VP Regulatory CMC) and represents the scaled commercial destination of Odylia's nonprofit drug development model.

TypeDirect peer
Description

Strategic collaboration partner with Odylia on inherited retinal disease gene therapies since 2019, with shared interest in the RPGRIP1 program. Also operates its own gene therapy pipeline and could be a future acquirer, co-development partner, or competitor depending on pipeline evolution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Odylia

Nonprofit Rare Disease Gene Therapy Developmentodylia.org

Odylia Therapeutics is a nonprofit 501(c)(3) biotech developing AAV gene therapies for ultra-rare inherited retinal diseases using the proprietary Anc80 vector platform. It serves patient advocacy groups through a three-program pipeline and a Brydge Solutions consulting service.

What Odylia does

Odylia Therapeutics is a nonprofit 501(c)(3) biotechnology organization founded in 2017 and headquartered in Atlanta, Georgia, that develops AAV-based gene therapies for rare diseases—predominantly inherited retinal dystrophies—that lack commercial interest from traditional pharmaceutical companies. The organization holds exclusive rights to the Anc80 AAV vector platform (an ancestral adeno-associated virus discovered in 2015 at Massachusetts Eye and Ear) for rare and ultra-rare retinal diseases, and operates a three-program pipeline: OT-004 (RPGRIP1 gene therapy for LCA6, CORD13, and juvenile retinitis pigmentosa, which holds FDA Orphan Drug and Rare Pediatric Disease Designations), a USH1C gene therapy partnered with the Usher 2020 Foundation, and an NPHP1 gene therapy co-developed with the NPHP1 Family Foundation and Boston Children's Hospital. Ancillary to the pipeline, Odylia runs Brydge Solutions, a consulting and portfolio management service for patient advocacy groups, and The Odylia Collective, a marketplace platform (merged with Comend in 2025) that connects patient advocacy groups with drug development service providers such as CROs and CDMOs.

Odylia's business model is philanthropic rather than commercial: the organization is funded by competitive research grants (e.g., $1.5 million from Foundation Fighting Blindness in 2024 and $249,719 from the Critical Path Institute in 2026), individual and corporate donations, and fee-based Brydge Solutions consulting engagements offered at reduced rates to patient groups. Manufacturing partnerships with Andelyn Biosciences (Anc80-capable CDMO) and Aldevron (plasmid DNA) support pipeline progression, while a strategic collaboration with PTC Therapeutics covers retinal disease development using the Anc80 system. Co-founder Luk Vandenberghe (Anc80 discoverer) and CEO/CSO Ashley Winslow lead scientific direction, supported by a Board of Directors with deep rare-disease industry expertise (Ultragenyx founder Emil Kakkis, former Sarepta/Alexion executives).

The organization serves three primary constituents: rare disease patient advocacy groups seeking to develop therapies for conditions with no commercial sponsor, early-stage biotechs and academic researchers needing translational guidance, and pharmaceutical companies pursuing nonprofit partnership models for ultra-rare indications. Go-to-market is community-led and event-driven, leveraging industry conferences (ASGCT, World Orphan Drug Congress), educational webinars, and direct patient-group engagement. As a pre-clinical stage nonprofit, Odylia has no commercial product revenue, and its measurable outputs are grant dollars secured, partnerships established, and IND-enabling milestones achieved across the pipeline.

Odylia firmographics

Firmographics
Name
Odylia
Legal name
Odylia Therapeutics
Website
https://odylia.org
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Odylia Therapeutics is a nonprofit 501(c)(3) biotech developing AAV gene therapies for ultra-rare inherited retinal diseases using the proprietary Anc80 vector platform. It serves patient advocacy groups through a three-program pipeline and a Brydge Solutions consulting service.
Ownership category
akta.pro rank

Odylia industry classification

Industry
Product category
Nonprofit Rare Disease Gene Therapy Development
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease gene therapy
  • AAV vector therapeutics
  • Nonprofit biotech
  • Retinal dystrophy treatments
  • Drug development consulting

Where Odylia is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Odylia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Donations and Charitable Contributions: Odylia is a 501(c)(3) nonprofit organization that relies on contributions from individuals, nonprofit organizations, patient groups, and corporate donors to fund drug development activities.
  2. Research Grants: Odylia receives competitive research grants from foundations and organizations such as the Critical Path Institute ($249,719 grant for USH1C gene therapy) and Foundation Fighting Blindness ($1.5 million Translational Research Award for RPGRIP1).
  3. Brydge Solutions Services: Odylia provides consulting and program management services to patient groups, early-stage biotech companies, and academic researchers through its Brydge Solutions initiative, offering services at reduced rates to patient groups.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels9 records

Odylia product offering

Product offering

Core offering

Odylia Therapeutics is a nonprofit biotech developing investigational AAV gene therapies for rare genetic diseases, with a primary focus on inherited retinal dystrophies. Its pipeline includes OT-004 (RPGRIP1), USH1C, and NPHP1 gene therapy programs built on the Anc80 AAV vector platform. The organization also operates Brydge Solutions, providing drug development consulting and portfolio management to patient advocacy groups, and runs The Odylia Collective (merged with Comend), a marketplace connecting patient groups with drug development service providers.

Product overview

Odylia Therapeutics is a nonprofit biotech that operates primarily through its gene therapy pipeline, offering three investigational AAV gene therapies (OT-004/RPGRIP1, USH1C, and NPHP1) built on exclusive Anc80 vector technology. The company complements its internal pipeline with Brydge Solutions—a consulting and portfolio management service for patient groups—and The Odylia Collective marketplace (merged with Comend) that connects patient advocacy groups with drug development service providers. Anc80 Resources provides technical information on the AAV vector platform. The Odylia Library offers educational content and landscape analyses to support the rare disease community.

Differentiator

Problem solved

Functional benefit

Brands

  • Brydge Solutions: A consulting and portfolio management service for rare disease patient groups, providing scientific team support, strategic briefs, landscape analyses, and portfolio management services.
  • The Odylia Collective

Products and services

  • OT-004 (RPGRIP1 Gene Therapy) Investigational AAV gene therapy utilizing the Anc80 vector for efficient RPGRIP1 gene transfer to treat vision loss in patients with Leber Congenital Amaurosis 6 (LCA6), Cone Rod Dystrophy 13 (CORD13), and juvenile retinitis pigmentosa caused by RPGRIP1 mutations.
  • USH1C Gene Therapy Investigational gene therapy designed to address vision loss in Usher Syndrome Type 1C by delivering a functional copy of the USH1C gene to retinal cells using an AAV delivery system. Developed in partnership with Usher 2020 Foundation.
  • NPHP1 Gene Therapy AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene, developed in co-development partnership with the NPHP1 Family Foundation and Boston Children's Hospital (Dr. Friedhelm Hildebrandt's team).
  • Brydge Solutions Consulting and program management services for rare disease patient groups, providing scientific expertise, strategic briefs, landscape analyses, and portfolio management to accelerate therapeutic development. Services offered at reduced rates to patient groups and include Science Team support, Strategic Briefs, Landscape Analyses, Portfolio Management, and Strategy Evaluations.
  • The Odylia Collective (merged with Comend) Centralized marketplace designed to make essential drug development resources findable and accessible for patient advocacy groups and the rare disease research community. Connects patient groups with service providers including manufacturers, clinical CROs, animal testing services, cell line producers, and biobanking services.

Quantifiable outcome

  • Accelerated timelines and reduced costs compared to traditional biotech model
  • +1 more outcomes

Companies that use Odylia

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Odylia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Odylia partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • Usher 2020 FoundationcoreStrategic or Co-development Partner · 20 May 2026Partnership to pursue treatment for Usher Syndrome Type 1C-associated vision loss. Preclinical studies supported by the foundation demonstrated successful gene delivery with expression of human USH1C transcript and protein, providing proof-of-concept.
  • ComendcoreStrategic or Co-development Partner · 13 May 2025Strategic partnership to launch a patient-driven platform for rare disease drug development. The Odylia Collective concept merged with Comend's platform to help patient advocacy groups identify, evaluate, and partner with service providers like CROs, academic groups, and drug discovery organizations. The partnership was formalized in late 2024 with platform launch planned for April 2025.
  • NPHP1 Family FoundationcoreStrategic or Co-development Partner · 5 May 2025Innovative co-development partnership to create an AAV-based gene replacement therapy for retinal dystrophy caused by NPHP1 gene mutations. Preclinical work scheduled throughout 2025, targeting IND submission and clinical trial in late 2027.
  • Boston Children's Hospital / Dr. Friedhelm HildebrandtcoreTechnology or Integration · 5 May 2025Collaboration for NPHP1 gene therapy program. Dr. Hildebrandt's team at Boston Children's Hospital is conducting natural history, dosing, and efficacy studies on two different NPHP1 mouse models. Dr. Hildebrandt is a renowned expert on nephrocystin genes and associated ciliopathies.
  • PURA Syndrome FoundationmajorStrategic or Co-development Partner · 17 December 2024Partnership to evaluate current state of research and clinical progress toward treatments for PURA Syndrome. Odylia provides scientific and strategic guidance to help the foundation seek new treatments and develop research strategies.
  • Smith Kingsmore Syndrome FoundationmajorStrategic or Co-development Partner · 17 September 2024Partnership to provide scientific and strategic guidance regarding current state of research and clinical progress toward treatments for Smith-Kingsmore syndrome. Odylia's work enables the foundation to deploy resources effectively and develop short- and long-term research strategies.
  • JEM TherapeuticsmajorStrategic or Co-development Partner · 1 March 2023Partnership to accelerate development of JEM's portfolio, starting with TECPR2-related disease (SPG49). Odylia develops and implements scientific strategy to accelerate development timelines and increase likelihood of success.
  • Andelyn BiosciencescoreTechnology or Integration · 31 January 2023Partnership with gene therapy CDMO to manufacture OT-004 (RPGRIP1 gene therapy) using the novel Anc80 AAV capsid. Andelyn has unique capabilities to manufacture this novel AAV capsid and bring the treatment to clinical trials.
  • CLOVES Syndrome CommunityminorStrategic or Co-development Partner · 21 October 2021Partnership to provide scientific and strategic guidance regarding research and clinical progress for CLOVES syndrome treatments. Odylia enables the community to deploy resources effectively and develop ongoing research strategies.
  • SATB2 Gene FoundationminorStrategic or Co-development Partner · 24 February 2021Partnership to provide scientific and strategic guidance regarding current state of research and understanding of SATB2-associated syndrome. Odylia enables the foundation to deploy resources appropriately to accelerate research.
  • PTC TherapeuticsmajorStrategic or Co-development Partner · 1 July 2019Strategic collaboration to develop novel gene therapies for rare inherited retinal diseases utilizing the Anc80 vector system. Lead program is RP-GRIP1 (RPGRIP1) for Leber Congenital Amaurosis 6 (LCA6).
  • AldevroncoreTechnology or Integration · 27 June 2018Partnership with contract manufacturing organization specializing in plasmid DNA production. Aldevron is a member of Odylia and serves as the exclusive provider of plasmid DNA for Odylia-sponsored projects.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Odylia competitors and assessment

Company assessment

Direct peers

  • Cystic Fibrosis Foundation: The pioneering nonprofit drug development organization that funded and incubated therapies now marketed by Vertex Pharmaceuticals. Operates an analogous mission-driven, patient-anchored model for ultra-rare genetic disease drug development, the exact organizational archetype Odylia aspires to replicate in retinal disease.
  • MeiraGTx: Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases (including achromatopsia, X-linked retinitis pigmentosa) as well as CNS and salivary gland conditions. Directly competes with Odylia's RPGRIP1, USH1C, and NPHP1 programs in the inherited retinal dystrophy space.
  • REGENXBIO: Clinical and commercial-stage AAV gene therapy platform company with approved therapy ABECMA-related assets and a broad pipeline including ABBV-RGX-314 for wet AMD and diabetic retinopathy. Operates the same AAV delivery platform category as Odylia's Anc80-based programs.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with a proprietary AAV discovery platform (Therapeutic Vector Evolution) developing treatments for rare diseases including choroideremia and other inherited retinal dystrophies. Competes directly with Odylia on next-generation AAV platforms for ultra-rare ophthalmic diseases.
  • Nanoscope Therapeutics: Clinical-stage biotechnology company developing gene therapies for inherited retinal diseases including retinitis pigmentosa and Stargardt disease. Directly comparable target indication space (inherited retinal dystrophies) and development stage to Odylia's OT-004 program.
  • Parent Project Muscular Dystrophy: Nonprofit organization that funds and accelerates Duchenne muscular dystrophy drug development, including direct investment in gene therapy programs and partnerships with Sarepta and other developers. Direct operational analog to Odylia's nonprofit biotech model applied to a different rare disease.
  • PTC Therapeutics: Strategic collaboration partner with Odylia on inherited retinal disease gene therapies since 2019, with shared interest in the RPGRIP1 program. Also operates its own gene therapy pipeline and could be a future acquirer, co-development partner, or competitor depending on pipeline evolution.

Broad incumbents

  • Spark Therapeutics (Roche): Acquired by Roche in 2019, Spark developed and commercializes LUXTURNA, the first FDA-approved AAV gene therapy for an inherited retinal dystrophy (RPE65-related). Sets the regulatory and commercial precedent for the exact disease category Odylia targets.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with multiple approved therapies and an active gene therapy pipeline including programs in ophthalmology. Shares board overlap with Odylia (Emil Kakkis as CEO, Khandan Baradaran as VP Regulatory CMC) and represents the scaled commercial destination of Odylia's nonprofit drug development model.

Others

  • Foundation Fighting Blindness: Largest nonprofit funder of retinal degenerative disease research, and a direct financial backer of Odylia via a $1.5M Translational Research Award. Functions as an adjacent ecosystem enabler/funder rather than a competitor, but shapes the competitive landscape by funding competing academic and commercial retinal disease programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Odylia social profiles

Digital presence

Odylia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Odylia leadership team

Management profile

Number of profiles

Profiles10 records

Odylia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Odylia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Odylia

What does Odylia do?

Odylia Therapeutics is a nonprofit biotech developing investigational AAV gene therapies for rare genetic diseases, with a primary focus on inherited retinal dystrophies. Its pipeline includes OT-004 (RPGRIP1), USH1C, and NPHP1 gene therapy programs built on the Anc80 AAV vector platform. The organization also operates Brydge Solutions, providing drug development consulting and portfolio management to patient advocacy groups, and runs The Odylia Collective (merged with Comend), a marketplace connecting patient groups with drug development service providers.

Is Odylia a public or private company?

Odylia is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Odylia founded?

Odylia was founded in 2017. It employs 11 to 50 people.

Where is Odylia based?

Odylia is headquartered in Atlanta, United States, in the North America region.

How does Odylia make money?

Three revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are research Grants and brydge Solutions Services.

Who are Odylia's main competitors?

Direct peers on record are Cystic Fibrosis Foundation, MeiraGTx, REGENXBIO, 4D Molecular Therapeutics, Nanoscope Therapeutics, Parent Project Muscular Dystrophy and PTC Therapeutics. Broad incumbents are Spark Therapeutics (Roche) and Ultragenyx Pharmaceutical. Foundation Fighting Blindness is listed as an others.

Does Odylia have an API?

No public API is recorded for Odylia.

What industry is Odylia in?

Odylia's product category is Nonprofit Rare Disease Gene Therapy Development. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesOdylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day eventOdylia Therapeutics hosted a Rare Disease Day event in Boston to discuss funding and collaboration for rare disease drug development. The nonprofit biotech is advancing a therapy for RPGRIP1-associated retinal dystrophy and has over 15 partnerships through its Brydge Solutions initiative.GlobeNewswireOdylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day eventOdylia Therapeutics hosted a Rare Disease Day event in Boston to discuss funding and collaboration for rare disease drug development. The nonprofit biotech is advancing a therapy for RPGRIP1-associated retinal dystrophy and two additional gene therapies, with over 15 partnerships through its Brydge Solutions initiative.Business InsiderOdylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day eventOdylia Therapeutics hosted a Rare Disease Day event in Boston to discuss funding and collaboration for rare disease drug development. The nonprofit biotech is advancing a therapy for RPGRIP1-associated retinal dystrophy and two additional gene therapies, with over 15 partnerships through its Brydge Solutions initiative.YahooOdylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day eventOdylia Therapeutics hosted a Rare Disease Day event in Boston to discuss funding and collaboration for rare disease drug development. The nonprofit biotech is advancing a therapy for RPGRIP1-associated retinal dystrophy and has over 15 partnerships through its Brydge Solutions initiative. It seeks further collaborations with biotech firms, investors, and patient groups.PR NewswireOdylia Therapeutics Announces Appointment of Two New Members to Board of DirectorsOdylia Therapeutics announced the appointment of Sharon M. Walker, Ph.D., J.D., and Brian Fenton to its Board of Directors. Sharon Walker, currently Senior Counsel at Sanofi, brings over 15 years of intellectual property experience in healthcare, while Brian Fenton brings over 30 years of biotechnology industry experience, including prior roles as Chief Business Officer at Translate Bio and in rare disease Business Development at Shire Pharmaceuticals. The company stated these appointments reflect its commitment to advancing a nonprofit model in rare disease drug development and will complement and expand the board's expertise.PR NewswirePTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia TherapeuticsPTC Therapeutics and Odylia Therapeutics announced a strategic collaboration to develop novel gene therapies for rare inherited retinal diseases using the Anc80 vector system. The partnership focuses on the RP-GRIP1 program targeting Leber Congenital Amaurosis 6, combining PTC's commercialization expertise with Odylia's ophthalmic research capabilities.